UNSPSC 51433705: Pelanserin hydrochloride

This classification denotes a serotonin antagonist C21H24N4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4J8I18ZP0A, chemically known as 3-(3-(4-phenyl-1-piperazinyl)propyl)-2,4(1h,3h)-quinazolinedione monohydrochloride, but more generally known as pelanserin hydrochloride, which bears US NIH Compound Identifier 65436. Most nations, for tariff and trade purposes, schedule pelanserin hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, PELANSERIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Pelanserin hydrochloride bears US NLM identifiers UMLS ID C2698754 and NCI Concept Code C76966. SMILES: C1CCC(CC1)N2CCN(CC2)CCCN3C(=O)C4CCCCC4[NH]C3=O.CL.

UNSPSC 51433705 Pelanserin hydrochloride is a Commodity code that represents a single pharmaceutical active ingredient, yet the recent state and local opportunities tagged to it actually span a much broader scope — generic multi-source pharmaceuticals, advanced life support medications, and direct-to-manufacturer prescription programs. State and local governments use this code as part of larger pharmaceutical procurement workflows where they are buying finished medications and OTC products for emergency medical services, health plan formularies, and institutional healthcare settings. Issuing bodies include city purchasing departments (notably the City of Tampa), state health and human services agencies (Texas Health and Human Services Commission), and state-administered cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP) that serve multiple participating jurisdictions across states. The work being solicited ranges from specific advanced life support drugs for fire rescue operations to multi-state procurement of generic pharmaceuticals distributed through authorized wholesalers to exploratory vendor-capability assessments for direct pharmaceutical contracting models.

Geographic activity spans Texas, Minnesota (with participating Oregon procurement), and Florida, with the cooperative purchasing vehicle (MMCAP) showing interstate reach. Representative recent opportunities include the City of Tampa's IFB for Advanced Life Support Medications (Bid No. 26-P-00188, due April 8, 2026, estimated contract value $40,000) for Tampa Fire Rescue, which solicited labetalol, epinephrine, adenosine, and diltiazem injections with firm pricing and nine-month minimum shelf life; MMCAP's RFP for Generic Multi Source Pharmaceuticals and OTC Products (due March 26, 2026), which establishes multiple vendor contracts for pharmaceuticals distributed through three authorized wholesalers across multiple state and local facilities with a two-year term and price-competitiveness weighting of 75 percent; and the Texas Health and Human Services Commission's RFI (HHS0017013, posted April 3, 2026) for direct-to-manufacturer prescription capabilities, which is a preliminary market-intelligence exercise preceding a future formal RFP. The SLBE sheltered-market designation and 5 percent bid discount appear in the Tampa procurement, and MMCAP requires compliance with cGMP, DSCSA, and FDA requirements with comprehensive insurance coverage documentation.